Beerman Jack T, Beaumont Gwendal G, Giabbanelli Philippe J
Department of Computer Science & Software Engineering, Miami University, Oxford, OH 45056, USA.
IMT Mines Ales, 6 Av. de Clavieres, 30100 Ales, France.
Vaccines (Basel). 2022 Oct 14;10(10):1716. doi: 10.3390/vaccines10101716.
The virus that causes COVID-19 changes over time, occasionally leading to Variants of Interest (VOIs) and Variants of Concern (VOCs) that can behave differently with respect to detection kits, treatments, or vaccines. For instance, two vaccination doses were 61% effective against the BA.1 predominant variant, but only 24% effective when BA.2 became predominant. While doses still confer protection against severe disease outcomes, the BA.5 variant demonstrates the possibility that individuals who have received a few doses built for previous variants can still be infected with newer variants. As previous vaccines become less effective, new ones will be released to target specific variants and the whole process of vaccinating the population will restart. While previous models have detailed logistical aspects and disease progression, there are three additional key elements to model COVID-19 vaccination coverage in the long term. First, the willingness of the population to participate in regular vaccination campaigns is essential for long-term effective COVID-19 vaccination coverage. Previous research has shown that several categories of variables drive vaccination status: sociodemographic, health-related, psychological, and information-related constructs. However, the inclusion of these categories in future models raises questions about the identification of specific factors (e.g., which sociodemographic aspects?) and their operationalization (e.g., how to initialize agents with a plausible combination of factors?). While previous models separately accounted for natural- and vaccine-induced immunity, the reality is that a significant fraction of individuals will be both vaccinated and infected over the coming years. Modeling the decay in immunity with respect to new VOCs will thus need to account for hybrid immunity. Finally, models rarely assume that individuals make mistakes, even though this over-reliance on perfectly rational individuals can miss essential dynamics. Using the U.S. as a guiding example, our scoping review summarizes these aspects (vaccinal choice, immunity, and errors) through ten recommendations to support the modeling community in developing long-term COVID-19 vaccination models.
导致新冠肺炎的病毒会随时间变化,偶尔会产生“感兴趣的变异株”(VOIs)和“值得关注的变异株”(VOCs),这些变异株在检测试剂盒、治疗方法或疫苗方面可能表现出不同的特性。例如,两剂疫苗对占主导地位的BA.1变异株的有效性为61%,但当BA.2占主导地位时,有效性仅为24%。虽然疫苗剂量仍能提供针对严重疾病后果的保护,但BA.5变异株表明,接种过针对先前变异株的几剂疫苗的个体仍有可能感染新的变异株。随着先前的疫苗效果降低,将推出新的疫苗来针对特定变异株,为人群接种疫苗的整个过程将重新开始。虽然先前的模型详细描述了后勤方面和疾病进展情况,但要长期模拟新冠肺炎疫苗接种覆盖率,还需要考虑另外三个关键因素。首先,民众参与定期疫苗接种活动的意愿对于长期有效的新冠肺炎疫苗接种覆盖率至关重要。先前的研究表明,几类变量会影响疫苗接种状况:社会人口统计学、健康相关、心理和信息相关的因素。然而,在未来的模型中纳入这些类别会引发关于特定因素识别(例如,哪些社会人口统计学方面的因素?)及其操作化(例如,如何用合理的因素组合初始化主体?)的问题。虽然先前的模型分别考虑了自然免疫和疫苗诱导的免疫,但实际情况是,在未来几年中,很大一部分人将既接种疫苗又感染病毒。因此,模拟针对新的VOCs的免疫力衰减需要考虑混合免疫。最后,模型很少假设个体犯错,尽管这种对完全理性个体的过度依赖可能会忽略重要的动态变化。以美国为例,我们的范围综述通过十条建议总结了这些方面(疫苗选择、免疫和错误),以支持建模界开发长期的新冠肺炎疫苗接种模型。